Terms: = Prostate cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Prognosis
5 results:
1. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract] [Full Text] [Related]
2. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract] [Full Text] [Related]
3. Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis.
Castellón EA; Valenzuela R; Lillo J; Castillo V; Contreras HR; Gallegos I; Mercado A; Huidobro C
Biol Res; 2012; 45(3):297-305. PubMed ID: 23283439
[TBL] [Abstract] [Full Text] [Related]
4. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
[TBL] [Abstract] [Full Text] [Related]
5. Expression of drug pathway proteins is independent of tumour type.
Zhang W; Shannon WD; Duncan J; Scheffer GL; Scheper RJ; McLeod HL
J Pathol; 2006 Jun; 209(2):213-9. PubMed ID: 16508919
[TBL] [Abstract] [Full Text] [Related]
